Lausanne-based Comphya SA, a clinical-stage MedTech company, recently closed an oversubscribed Series A financing round, raising €8 million. This funding includes the conversion of existing convertible loans. Comphya develops CaverSTIM, an innovative implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication.
Comphya, a prominent Swiss startup, offers CaverSTIM as the first implantable device designed to restore erectile function by activating cavernous nerves. This represents a significant advancement in neurostimulation technology. Existing treatments, such as intrapenile injections or penile implants, often present painful and problematic options for patients. Comphya aims to provide a physiological and improved quality of life solution.
Advancing Clinical Trials and Market Entry
Proceeds from the Series A round will significantly advance Comphya's clinical development. The company will launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval in January 2025. Furthermore, Comphya plans preparations for a pivotal U.S. clinical trial scheduled for 2026. This funding also expands Comphya’s ongoing clinical trial in Australia, recruiting additional patients.
Encouraging clinical results emerged from the company’s first-in-human study in Australia. Patients undergoing robotic-assisted prostatectomy maintained good erectile function postoperatively without adjunctive therapies. These early outcomes highlight CaverSTIM's potential to address a significant gap in post-prostatectomy care. Pim van Wesel assumed the CEO role in May 2025, guiding the company's clinical growth and strategic execution.